Literature DB >> 15262127

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

Sandra Tomek1, Peter Horak, Ingrid Pribill, Griet Haller, Max Rössler, Christoph C Zielinski, Dietmar Pils, Michael Krainer.   

Abstract

BACKGROUND: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, is a recently identified cytokine that preferentially kills transformed cells while sparing most normal cells.
METHODS: We investigated the ability of TRAIL alone and TRAIL in combination with cytotoxic drugs to induce apoptosis in six ovarian cancer cell lines. To get some insight into the resistance to TRAIL, the expression of TRAIL receptors and selected downstream signaling elements was determined.
RESULTS: TRAIL induced significant apoptosis (up to 80%) in three out of six ovarian cancer cell lines (MZ-26, CaOV-3, ES-2). In A2780 and A2780ADR cells, resistance to TRAIL-induced apoptosis correlated with their lack of DR4-expression. MZ-15 cells, which expressed the processed form of FLIP(L), p43 (FADD-like IL-1beta-converting enzyme (FLICE)-like inhibitory protein (FLIP)), and FLIP(S), were resistant to TRAIL in spite of the presence of DR4. When TRAIL-resistant cell lines were co-incubated with routinely used cytotoxic agents, TRAIL exerted a synergistic effect leading to apoptosis rates unachievable by incubation with cytotoxic agents alone.
CONCLUSION: The ability of TRAIL to induce apoptosis in ovarian cancer cells as well as to potentiate the activity of chemotherapeutic agents even in cell lines that are resistant to TRAIL-induced cytotoxicity is a powerful promise in the fight against this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262127     DOI: 10.1016/j.ygyno.2004.04.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

1.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

2.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 3.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

4.  Mitochondrial division inhibitor 1 (mdivi-1) enhances death receptor-mediated apoptosis in human ovarian cancer cells.

Authors:  Jingnan Wang; Karyn Hansen; Robert Edwards; Bennett Van Houten; Wei Qian
Journal:  Biochem Biophys Res Commun       Date:  2014-11-13       Impact factor: 3.575

5.  Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.

Authors:  Penny Clarke; Kenneth L Tyler
Journal:  Apoptosis       Date:  2007-01       Impact factor: 4.677

Review 6.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

7.  Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis.

Authors:  Sibaji Sarkar; Douglas V Faller
Journal:  Nucleic Acid Ther       Date:  2013-05-02       Impact factor: 5.486

8.  Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Authors:  Ioannis Alagkiozidis; Andrea Facciabene; Carmine Carpenito; Fabian Benencia; Zdenka Jonak; Sarah Adams; Richard G Carroll; Phyllis A Gimotty; Rachel Hammond; Gwen-äel Danet-Desnoyers; Carl H June; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2009-12-10       Impact factor: 5.531

9.  2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts.

Authors:  Sumie Kato; Anil Sadarangani; Soledad Lange; Ana M Delpiano; Macarena Vargas; Jorge Brañes; Jorge Carvajal; Stanley Lipkowitz; Gareth I Owen; Mauricio A Cuello
Journal:  Reprod Sci       Date:  2008-11       Impact factor: 3.060

10.  ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death.

Authors:  Stancy Joseph; Victoria E Deneke; Karen D Cowden Dahl
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.